Intermediate-dose melphalan compared with myeloablative treatment in multiple myeloma: long-term follow-up of the Dutch Cooperative Group HOVON 24 trial
Autor: | Pieter Sonneveld, Bronno van der Holt, Christine M. Segeren, Edo Vellenga, Alexandra J. Croockewit, Gregor E.G. Verhoef, Jan J. Cornelissen, Martijn R. Schaafsma, Marinus H.J. van Oers, Pierre W. Wijermans, Petra H.M. Westveer, Henk M. Lokhorst |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2007 |
Předmět: | |
Zdroj: | Haematologica, Vol 92, Iss 7 (2007) |
Druh dokumentu: | article |
ISSN: | 0390-6078 1592-8721 |
DOI: | 10.3324/haematol.11168 |
Popis: | Background and Objectives The Dutch-Belgian HOVON group performed a randomized phase 3 trial to compare single non-myeloablative intensive treatment with double, intensive treatment in previously untreated patients with multiple myeloma (MM).Design and Methods Three hundred and three patients with stage II/III MM were randomized after VAD induction chemotherapy to receive two cycles of non-myeloablative intermediate-dose melphalan (70 mg/m2) (single treatment) or the same regimen followed by cyclophosphamide 120 mg/kg iv plus total body irradiation (TBI) 9 Gy and autologous stem cell transplantation (double, intensive treatment). In both treatment arms interferon αIIa was given as maintenance until relapse/progression.Results A significantly higher proportion of patients achieved a complete remission (CR) on protocol treatment with double, intensive therapy (32% vs 13%, p |
Databáze: | Directory of Open Access Journals |
Externí odkaz: |